-+ 0.00%
-+ 0.00%
-+ 0.00%
Assessing Stepan (SCL) Valuation After First Quarter 2026 Profitability Setback
Share
Listen to the news

First quarter earnings trigger fresh focus on Stepan

Stepan (SCL) is drawing attention after first quarter 2026 results showed sales of US$604.51 million alongside a net loss of US$41.41 million, compared with net income in the prior year period.

See our latest analysis for Stepan.

The first quarter loss comes after a period where momentum has softened, with an 11.66% year to date share price return and a 12.74% one year total shareholder return set against a 37.39% three year total shareholder return decline.

If Stepan's recent swing in profitability has you reassessing the chemicals space, this can be a useful moment to broaden your research with 18 top founder-led companies

With Stepan sharing a 3 year total shareholder return decline alongside an intrinsic discount estimate of around 62%, the key question is whether this weakness signals undervaluation or whether the market already reflects its future growth potential.

Most Popular Narrative: 29.8% Undervalued

Analysts placing fair value at $75, versus Stepan's last close at $52.66, see a sizeable valuation gap that rests on specific operating and earnings assumptions.

The startup of the new Pasadena, Texas site is expected to reach full contribution in the second half of 2025, which could boost volume growth and supply chain savings. This is likely to impact revenue and margins positively.

Read the complete narrative.

Analysts are banking on steadier margins, measured revenue expansion and a future earnings multiple below the sector average. They may be evaluating which mix of growth, profitability and discounts supports that $75 fair value.

Result: Fair Value of $75 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, you also need to weigh ongoing pressures, including negative free cash flow and softer Rigid Polyol demand. These factors could challenge the margin and earnings narrative.

Find out about the key risks to this Stepan narrative.

Another View: Earnings Multiple Sends a Mixed Signal

While the analyst narrative leans on earnings growth and discounted cash flows, the current P/E of 25.5x tells a different story. It sits below the US Chemicals industry average of 29.6x, yet above the fair ratio estimate of 21.4x, which suggests some valuation risk if sentiment cools.

If you prefer to anchor on earnings multiples, this gap between the current P/E, peers and the fair ratio is worth stress testing against your own expectations for Stepan's margins and growth. It is also worth asking whether the market might eventually drift closer to that lower fair ratio or hold its ground at a premium See what the numbers say about this price — find out in our valuation breakdown.

NYSE:SCL P/E Ratio as at Apr 2026
NYSE:SCL P/E Ratio as at Apr 2026

Next Steps

Mixed messages on value and risk can be useful, but your view matters most. Review the full picture and weigh the company's 2 key rewards and 2 important warning signs

Looking for more investment ideas?

Do not stop your research with a single stock; use the screener to spot other opportunities that match your style and keep your watchlist ahead of the crowd.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending